AlzeCure Pharma, a pharmaceutical company specialising in neurological disorders, has released a scientific article on the potential of Trk receptor modulation in treating Alzheimer's disease.
The article, which is titled 'Positive allosteric modulators of Trk-receptors for the treatment of Alzheimer's disease' has been published in Pharmaceuticals and focuses on the history, biology and concept behind Trk positive allosteric modulators (Trk-PAMs).
It also delves into the potential of the novel drug class in neurological disease.
The company has managed to progress one of the first Trk-PAMs, ACD856, to clinical trials, with the therapeutic currently being prepared for Phase II trials in patients.
AlzeCure and Eisai are currently the only two companies who have managed to progress a Trk-PAM to clinical trials, and both companies have reported promising results in early phase studies.
Previous preclinical studies gave shown that Trk-PAMs can:
- Enhance the presence of BDNF and NGF, leading to enhanced cognition
- Strengthen communication between nerve cells, improving memory and cognition
- Offer neuroprotective, anti-inflammatory and disease-modifying benefits
"The publication shows the exciting development possibilities for Trk-PAM substances such as ACD856, as well as the pharmacological mechanism behind them. With the positive Phase I clinical data we have previously obtained, we see very interesting further development paths for ACD856. Substances such as Trk-PAMs may well be a future complement to anti-amyloid treatments, such as Donanemab and Lecanemab, for patients with Alzheimer's disease," said the Head of Discovery and Research at AlzeCure Pharma, Pontus Forsell.
“There is a great medical need for effective and safe treatments for Alzheimer's disease. The new data we have published over the past year supporting both memory-enhancing and disease-modifying effects show very exciting potential in our project ACD856 and strengthen our out-licensing opportunities," said Martin Jönsson, CEO of AlzeCure Pharma.
